Pravastatin

Base Information

• Chemical Name: Pravastatin
• CAS No.: 81093-37-0
• Deprecated CAS: 103382-89-4
• Molecular Formula: C₂₃H₃₆O₇
• Molecular Weight: 424.535
• European Community (EC) Number: 689-360-3
• UNII: KXO2KT9N0G
• DSSTox Substance ID: DTXSID6023498
• Nikkaji Number: J139.432K
• Wikipedia: Pravastatin
• Wikidata: Q1240093
• NCI Thesaurus Code: C62070
• RXCUI: 42463
• Pharos Ligand ID: 79Z7FTH2WZ71
• Metabolomics Workbench ID: 42583
• ChEMBL ID: CHEMBL1144
• Mol file: 81093-37-0.mol

Synonyms:Apo Pravastatin;Apo-Pravastatin;Bristacol;CS 514;CS-514;CS514;Elisor;Eptastatin;Lin Pravastatin;Lin-Pravastatin;Lipemol;Liplat;Lipostat;Mevalotin;Nu Pravastatin;Nu-Pravastatin;Prareduct;Pravachol;Pravacol;Pravasin;Pravastatin;Pravastatin Monosodium Salt, (6 beta)-Isomer;Pravastatin Sodium;Pravastatin Sodium Salt;Pravastatin tert Octylamine Salt;Pravastatin tert-Octylamine Salt;Pravastatin, (6 beta)-Isomer;RMS 431;RMS-431;RMS431;Selektine;Sodium Salt, Pravastatin;SQ 31,000;SQ 31000;SQ-31,000;SQ-31000;SQ31,000;SQ31000;Vasten

Chemical Property of Pravastatin

Chemical Property:

• Appearance/Colour: Off-white Cryst.
• Vapor Pressure: 9.15E-19mmHg at 25°C
• Melting Point: 171.2-173 °C
• Refractive Index: 1.554
• Boiling Point: 634.5 °C at 760 mmHg
• PKA: 4.31±0.10(Predicted)
• Flash Point: 213.2 °C
• PSA: 127.12000
• Density: 1.21g/cm³
• LogP: 1.10570
• Storage Temp.: 2-8°C
• Solubility.: H2O: 19 mg/mL
• XLogP3: 1.6
• Hydrogen Bond Donor Count: 4
• Hydrogen Bond Acceptor Count: 7
• Rotatable Bond Count: 11
• Exact Mass: 424.24610348
• Heavy Atom Count: 30
• Complexity: 656

Purity/Quality:

97%-102% ^*data from raw suppliers

PravastatinSodium-d9 ^*data from reagent suppliers

Safty Information:

• Pictogram(s): F, C
• Hazard Codes: F,C
• Statements: 11-34
• Safety Statements: 16-26-36/37/39-45

MSDS Files:

SDS file from LookChem

Useful:

• Drug Classes: Antilipemic Agents
• Canonical SMILES: CCC(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC(CC(CC(=O)O)O)O)O
• Isomeric SMILES: CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)O)O)O)O
• Recent ClinicalTrials: A Study to Evaluate the Drug-drug Interaction Potential of BMS-986196 in Healthy Participants
• Recent EU Clinical Trials: A Double blind randomized phase III study of pravastatin vs placebo as primary prevention of severe subcutaneous breast fibrosis in hyper-radiosensitive identified patients with breast cancer
• Recent NIPH Clinical Trials: HMG-CoA Reductase Inhibitor for postmenopausal patients used as Arterial stiffness (ASI) index ; A Phase II randomized controlled study
• Description: Pravastatin is the third HMG-CoA reductase inhibitor introduced for the treatment of atherosclerosis. Compared with lovastatin and simvastatin launched earlier, pravastatin is equipotent as an HMG-CoA reductase inhibitor in vitro, yet it is reported to be more tissue-selective.
• Uses: antiglaucoma,
• Therapeutic Function: Antihyperlipidemic

Technology Process of Pravastatin

There total 7 articles about Pravastatin which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield: 85.4%

mevastatin (73573-88-3,58948-09-7) → pravastatin (81093-37-0,81131-74-0,250737-12-3)

Guidance literature:

Reference yield:

pravastatin sodium salt (81131-70-6,81176-41-2,124917-23-3) → pravastatin (81093-37-0,81131-74-0,250737-12-3)

Guidance literature:

With hydrogenchloride; In water; pH=4.0;

Reference yield:

Compactin sodium salt → pravastatin (81093-37-0,81131-74-0,250737-12-3)

Guidance literature:

With carbenicillin; isopropyl β-D-thiogalactopyranoside; glycerol; at 28 ℃; for 24h; pH=7.4; aq. phosphate buffer;

DOI:10.1271/bbb.80627

upstream raw materials:

3,5-bis-epi-compactin

mevastatin

pravastatin sodium salt

Downstream raw materials:

pravastatin sodium salt

Sodium; 3,5-dihydroxy-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-((S)-2-methyl-butyryloxy)-1,2,6,7,8,8a-hexahydro-naphthalen-1-yl]-heptanoate

pravastatin lactone

(S)-2-Methyl-butyric acid (1S,3R,4aS,7S,8S,8aS)-8-(2-{(4R,6S)-6-[2-(tert-butyl-diphenyl-silanyloxy)-ethyl]-2,2-dimethyl-[1,3]dioxan-4-yl}-ethyl)-3-hydroxy-7-methyl-decahydro-naphthalen-1-yl ester

Refernces

• 1、 -. "Fermentation Medias and Processes Thereof". Page/Page column. . Retrieved 2014/05/25.
• 2、 -. "Methods for predicting the response to statins". . . Retrieved 2011/10/13.